Table 2 Frequency of adverse events observed in ⩾10% of patients

From: Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

 

Grade

Toxicity

2

3

4

5

Anaemia

11 (19%)

1 (2%)

  

Anoraexia

6 (10%)

   

Diarrhoea

6 (10%)

   

Fatigue

18 (31%)

1 (2%)

  

Hypertension

6 (10%)

1 (2%)

1 (2%)

 

Infection

13 (22%)

4 (7%)

1 (2%)

 

Mucositis

11 (19%)

   

Nausea/emesis

11 (19%)

   

Neutropaenia

15 (25%)

9 (15%)

5 (8%)

 

Proteinuria

6 (10%)

1 (2%)

  

Rash

6 (10%)

   

Thrombosis

 

4 (7%)

2 (3%)

1 (2%)

Transaminase elevation

6 (10%)

1 (2%)

  
Back to article page